News
Public · Published
Canaccord Genuity maintains AtriCure at Buy, raises price target to $67 from $55
Canaccord Genuity kept its Buy rating on AtriCure and raised its price target to $67 from $55, a 21.8% increase. The new target implies 2.2% upside from the November 4 closing price of $65.53.
Published:
Updated:
What happened
Canaccord Genuity kept its Buy rating on AtriCure and raised its price target to $67 from $55, a 21.8% increase. The new target implies 2.2% upside from the November 4 closing price of $65.53.
Confirmed
Global impact / market context
A price target is an analyst’s estimate, not a guaranteed outcome. The revised $67 target sits only slightly above the cited closing price, so it signals limited projected share-price gain from that reference point; the rating remains Buy, but the article reports no change to AtriCure’s business or financial results.
Analyst inference
The five recent analyst targets listed range from $62 to $70, placing Canaccord’s $67 target within that spread. This range shows differing views among analysts; targets are estimates and do not establish what the shares will actually be worth or how investors will trade them.
Confirmed
What to watch
- Compare future analyst updates with the current $62–$70 target range; changes in those estimates could alter investors’ expectations for AtriCure’s share value. Analyst inference
- Watch for company results or guidance in later reporting that could support or challenge the assumptions behind the $67 target; none are provided here. Analyst inference
- The article reports Canaccord’s Buy rating and higher target, but gives no details about the analysis or business evidence supporting the revision. Confirmed
Evidence
- Original source link unavailable